AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.
January 27th 2022
AlgiPharma was featured in DelveInsights’s “Cystic Fibrosis Pipeline Insight, 2022” report that provides insight on company and pipeline activities in the Cystic Fibrosis therapeutics landscape.
The report highlights around 60+ products under development by companies working on novel opportunities that could influence Cystic Fibrosis treatment. The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.
See also GlobalNewswire summary.
About AlgiPharma AS:
AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.
AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.
AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).
AlgiPharma is a privately owned company registered and domiciled in Norway.
For additional information contact:
Yngvar P. Berg, CEO: email@example.com
Arne Dessen, COO and Chairman of the Board: firstname.lastname@example.org